(From left) Now Jung, CEO of VaxCell-Bio, and Cho Wook-je, CEO of Yuhan Corporation. /Courtesy of Yuhan Corporation

Yuhan Corporation will take charge of the domestic sales and distribution of VaxCell-Bio's pet immune cancer treatment.

Yuhan Corporation recently announced on the 13th that it has signed a business agreement with VaxCell-Bio regarding the marketing and sales of the domestic first canine-specific immune cancer treatment, "BoxLukin-15."

VaxCell-Bio will continue its research and development, including the expansion of indications for BoxLukin-15, while supplying the new drug. Yuhan Corporation will utilize its specialized animal medicines marketing organization and nationwide distribution network to exclusively market and sell BoxLukin-15 in the domestic market for three years.

BoxLukin-15 was approved last year as the first canine-specific immune cancer treatment in South Korea. Last month, efforts were made to expand its indication to lymphoma. Recently, the proportion of aging dogs over 9 years old has reached 41.4%, and tumor occurrences due to pet aging are increasing. Tumors are the leading cause of death in aging dogs.

Cho Wook-je, CEO of Yuhan Corporation, said, "I expect that by officially supplying BoxLukin-15, a third-generation immune cancer treatment with fewer side effects than existing anticancer drugs, it will be of great help to pets suffering from cancer and their guardians."

Lee Jeoong, CEO of VaxCell-Bio, noted, "I expect that combining Yuhan Corporation's solid professional marketing organization and nationwide distribution network with the accumulated know-how and technological capabilities of BoxLukin-15 will create synergy effects," adding that, "As cooperation between the two companies strengthens along with the expansion of indications for BoxLukin-15, market demand will also increase."

Meanwhile, Yuhan Corporation has previously launched the pet joint injection "AniConju" and the treatment for cognitive dysfunction syndrome "Zedacure." VaxCell-Bio has recently submitted an application to expand the indication of BoxLukin-15 from mammary tumors to lymphoma to the Animal and Plant Quarantine Agency. Research is also underway to expand indications to include feline diseases.